Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  ERYTECH Pharma    ERYP   FR0011471135

ERYTECH PHARMA

(ERYP)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
06/13/2019 06/14/2019 06/17/2019 06/18/2019 06/19/2019 Date
6.38(c) 6.49(c) 6.39(c) 6.24(c) 6.24 Last
6 367 12 204 18 935 27 453 4 197 Volume
-2.00% +1.72% -1.54% -2.35% 0.00% Change
More quotes
Financials (EUR)
Sales 2019 8,23 M
EBIT 2019 -54,4 M
Net income 2019 -56,5 M
Finance 2019 70,9 M
Yield 2019 -
Sales 2020 15,9 M
EBIT 2020 -49,4 M
Net income 2020 -50,2 M
Finance 2020 17,2 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 5,29x
EV / Sales2020 6,13x
Capitalization 114 M
More Financials
Company
ERYTECH Pharma is a French biopharmaceutical company providing new prospects for cancer patients. By encapsulating the asparaginase enzyme in red blood cells, has developed eryaspase/GRASPA®, an innovative treatment that destroys cancerous cells through starvation while significantly reducing side... 
More about the company
Surperformance© ratings of ERYTECH Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on ERYTECH PHARMA
05/31ERYTECH PHARMA : Announces the Availability of the Documents for its Annual Gene..
GL
05/13ERYTECH PHARMA : Announces FDA's Authorization to Proceed with Phase 3 Trial for..
AQ
05/13ERYTECH PHARMA : Announces FDA's Authorization to Proceed with Phase 3 Trial for..
AQ
05/06ERYTECH PHARMA : Provides Business Update and Reports Financial Results for Firs..
GL
05/06ERYTECH PHARMA : Provides Business Update and Reports Financial Results for Firs..
AQ
05/06ERYTECH PHARMA : Provides Business Update and Reports Financial Results for Firs..
GL
05/06ERYTECH Provides Business Update and Reports Financial Results for First Qua..
GL
05/06ERYTECH PHARMA : proposes the appointment of Dr. Jean-Paul Kress as Chairman of ..
GL
05/06ERYTECH PHARMA : proposes the appointment of Dr. Jean-Paul Kress as Chairman of ..
AQ
05/02ERYTECH PHARMA : to Host on May 7, 2019 First Quarter Conference Call and Busine..
PU
More news
Analyst Recommendations on ERYTECH PHARMA
More recommendations
Sector news : Bio Therapeutic Drugs
02:24pPFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
09:05aGILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
06/18PFIZER : Expands Cancer-Treatment Lineup
DJ
06/17ARRAY BIOPHARMA : Pfizer makes $10.6 billion cancer bet in cash deal for Array B..
RE
More sector news : Bio Therapeutic Drugs
Chart ERYTECH PHARMA
Duration : Period :
ERYTECH Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 28,1 €
Spread / Average Target 340%
EPS Revisions
Managers
NameTitle
Gil Beyen Chairman, CEO & Head-Investor Relations
Eric Soyer Chief Operating & Financial Officer
Iman El-Hariry Chief Medical Officer
Alexander Scheer Chief Scientific Officer
Philippe Archinard Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ERYTECH PHARMA-0.16%128
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB13.49%10 857
SAREPTA THERAPEUTICS INC21.25%8 523